You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Zanubrutinib

Showing 51 - 75 of 104
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements,

Recruiting
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • +4 more
  • Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
  • R-CHOP; R-DA-EPOCH; R-HD MTX
  • Jinan, Shandong, China
    Department of Hematology, Shandong Provincial Hospital
Dec 7, 2021

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +9 more
  • Adelaide, Australia
  • +12 more
Jan 6, 2023

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Nanjing, Nanjin (Zanubrutinib, Lenalidomide, Rituximab)

Recruiting
  • Non Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib
  • +6 more
  • Nanjing, Jiangsu, China
  • +1 more
Mar 9, 2022

Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic

Not yet recruiting
  • Recurrent Transformed Chronic Lymphocytic Leukemia
  • +7 more
  • Biospecimen Collection
  • +9 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 15, 2023

CNS Lymphoma Trial in Zhengzhou (Rituximab, Lenalidomide, Zanubrutinib, Lenalidomide, Zanubrutinib, Lenalidomide)

Recruiting
  • Central Nervous System Lymphoma
  • Rituximab, Lenalidomide, Zanubrutinib
  • +2 more
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 16, 2021

Diffuse Large B Cell Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Zanubrutinib and RCHOP)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Rituximab, Lenalidomide, Zanubrutinib and RCHOP
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Mar 21, 2022

Richter Transformation Trial in Austria, Denmark, Germany (Tislelizumab, Zanubrutinib)

Recruiting
  • Richter Transformation
  • Tislelizumab
  • Zanubrutinib
  • Vienna, Austria
  • +11 more
Mar 8, 2022

Healthy, Male Trial in Daytona Beach (Zanubrutinib, Rifabutin)

Completed
  • Healthy
  • Male
  • Daytona Beach, Florida
    Covance Clinical Research Unit
Aug 30, 2021

Mantle Cell Lymphoma Trial in Guangzhou (R-CHOP/R-DHAOx; Zanubrutib(induction); ASCT conditioning ; Zanubrutinib(Maintenance))

Recruiting
  • Mantle Cell Lymphoma
  • R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Aug 24, 2021

Lymphoma, Leukemia Trial in Australia, China (Zanubrutinib, Tislelizumab)

Completed
Has Results
  • Lymphoma
  • Leukemia
  • Darlinghurst, New South Wales, Australia
  • +9 more
Mar 16, 2022

Primary Vitreoretinal Lymphoma Trial in Beijing (Methotrexate, Rituximab, Zanubrutinib)

Recruiting
  • Primary Vitreoretinal Lymphoma
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 19, 2021

High Risk CLL, Chronic Lymphocytic Leukemia Trial (VenObi+Ven or VenObi+VenZan)

Not yet recruiting
  • High Risk CLL
  • Chronic Lymphocytic Leukemia
  • VenObi+Ven or VenObi+VenZan
  • (no location specified)
Jul 26, 2022

B-cell Lymphoma Trial in China (Zanubrutinib)

Completed
Has Results
  • B-cell Lymphoma
  • Zanubrutinib
  • Beijing, Beijing, China
  • +3 more
Sep 26, 2021

COVID-19 Pulmonary Complications, COVID-19 Trial in United States (Zanubrutinib, Supportive Care, Placebo)

Completed
Has Results
  • COVID-19 Pulmonary Complications
  • COVID-19
  • Zanubrutinib
  • +2 more
  • Scottsdale, Arizona
  • +17 more
Feb 25, 2022

Diffuse Large B Cell Lymphoma Trial in Wenzhou (Zanubrutinib+Rituximab+Lenalidomide, RCHOP/RCDOP)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Wenzhou, Zhejiang, China
    First Affiliated Hospital of Wenzhou Medical University
Jun 20, 2022

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma Trial in China (Zanubrutinib)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • Zanubrutinib
  • Hefei, Anhui, China
  • +21 more
Mar 2, 2022

Non-GCB/ABC DLBCL Trial in Suzhou (Zanubrutinib, Rituximab, Cyclophosphamide)

Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • Zanubrutinib
  • +5 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 12, 2021

Relapsed/Refractory DLBCL Trial in China (Zanubrutinib, Lenalidomide)

Recruiting
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Beijing, Beijing, China
  • +9 more
Aug 11, 2021

Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos Trial in Shanghai (Zanubrutinib, Tislelizumab)

Recruiting
  • Primary Mediastinal Large B Cell Lymphoma
  • EBV-Positive DLBCL, Nos
  • Shanghai, Shanghai, China
    Ruijin Hospital
Mar 29, 2021

Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Zanubrutinib)

Recruiting
  • Chronic Lymphoid Leukemia
  • Aachen, Germany
  • +20 more
Oct 5, 2021

DLBCL, Transformed Follicular Lymphoma to DLBCL, Transformed Marginal Zone Lymphoma to DLBCL Trial in Columbus

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Diffuse Large B-cell Lymphoma Trial in China (Zanubrutinib)

Completed
Has Results
  • Diffuse Large B-cell Lymphoma
  • Zanubrutinib
  • Beijing, Beijing, China
  • +10 more
Oct 11, 2021

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib plus R-ICE, Decitabine plus R-ICE, Chidamide plus R-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib plus R-ICE
  • +4 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Apr 26, 2022

Waldenström Macroglobulinemia Trial in United States (Zanubrutinib)

No longer available
  • Waldenström Macroglobulinemia
  • Zanubrutinib
  • Mobile, Alabama
  • +19 more
Jun 8, 2021

Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6

Not yet recruiting
  • Grade 3b Follicular Lymphoma
  • +5 more
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Jun 6, 2023